William Blair Issues Positive Outlook for NKTR Earnings

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at William Blair boosted their Q1 2025 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a report released on Thursday, March 13th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will post earnings of ($0.19) per share for the quarter, up from their previous forecast of ($0.22). William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. William Blair also issued estimates for Nektar Therapeutics' Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.88) EPS.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.33. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. The firm had revenue of $29.18 million during the quarter, compared to the consensus estimate of $36.65 million.

A number of other analysts have also recently weighed in on NKTR. B. Riley assumed coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $4.00 price target for the company. Oppenheimer raised shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price target for the company in a research report on Friday, March 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $6.50 price target on shares of Nektar Therapeutics in a research report on Thursday, March 13th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $4.92.

Remove Ads

Nektar Therapeutics Stock Down 3.3 %

Shares of Nektar Therapeutics stock traded down $0.03 during trading on Monday, hitting $0.87. 521,466 shares of the company were exchanged, compared to its average volume of 1,859,831. The firm has a 50 day moving average price of $0.87 and a 200 day moving average price of $1.07. Nektar Therapeutics has a fifty-two week low of $0.65 and a fifty-two week high of $1.93. The stock has a market capitalization of $160.11 million, a price-to-earnings ratio of -1.03 and a beta of 0.65.

Insider Buying and Selling at Nektar Therapeutics

In other news, insider Mark Andrew Wilson sold 33,402 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the transaction, the insider now owns 351,892 shares of the company's stock, valued at approximately $316,702.80. This trade represents a 8.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 67,476 shares of company stock valued at $64,477 in the last ninety days. Insiders own 3.71% of the company's stock.

Hedge Funds Weigh In On Nektar Therapeutics

Large investors have recently modified their holdings of the stock. Mackenzie Financial Corp raised its stake in Nektar Therapeutics by 801.4% during the fourth quarter. Mackenzie Financial Corp now owns 469,769 shares of the biopharmaceutical company's stock worth $437,000 after acquiring an additional 417,651 shares during the period. US Asset Management LLC bought a new position in shares of Nektar Therapeutics during the 4th quarter valued at about $31,000. Woodline Partners LP boosted its position in shares of Nektar Therapeutics by 187.3% during the 4th quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company's stock valued at $4,626,000 after purchasing an additional 3,242,841 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Nektar Therapeutics during the 4th quarter valued at about $130,000. Finally, Two Sigma Investments LP boosted its position in shares of Nektar Therapeutics by 12.8% during the 4th quarter. Two Sigma Investments LP now owns 1,537,355 shares of the biopharmaceutical company's stock valued at $1,430,000 after purchasing an additional 174,185 shares in the last quarter. Institutional investors own 75.88% of the company's stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.